Capuano, Cristina http://orcid.org/0000-0002-6747-3836
Pighi, Chiara http://orcid.org/0000-0001-6163-0135
Maggio, Roberta http://orcid.org/0000-0001-8319-4418
Battella, Simone http://orcid.org/0000-0002-1882-1451
Morrone, Stefania http://orcid.org/0000-0003-2441-9749
Palmieri, Gabriella http://orcid.org/0000-0002-1467-1417
Santoni, Angela http://orcid.org/0000-0003-1206-7731
Klein, Christian
Galandrini, Ricciarda http://orcid.org/0000-0003-2660-1456
Funding for this research was provided by:
Italian Ministry of University and Research (RBSI14022M)
Article History
Received: 19 September 2019
Accepted: 4 January 2020
First Online: 16 January 2020
Compliance with ethical standards
:
: Christian Klein declares employment, patents and stock ownership with Roche Glycart AG, Schlieren, Switzerland. All other authors declare that they have no conflict of interests.
: All procedures involving human participants were in accordance with the ethical standards of the institutional research committee and with 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Sapienza University of Rome (approval number 639/16 RIF/CE 4179).
: All experiments were performed after obtaining written informed consent from patients and healthy donors. The informed consent was taken at the beginning of the study to use data and materials for research and publication of this study.
: RPMI 8866 cell line was purchased by American Type Culture Collection, and Raji cell line was provided by Dr. F.D. Batista. Cells were authenticated (last testing May 2019) by morphology, growth and immunophenotypic characteristics, biologic behavior according to the provider recommendations, and routinely tested for mycoplasma contamination by EZ-PCR Mycoplasma test kit (#20–700-20, Biological Industries). All cell lines were kept in culture for less than two consecutive months.